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Abstract
Background and aim: Use of ultrasound scans early in pregnancy is increasing, but we have limited knowledge
about the actual prevalence, associated decision-making and impact on expectant women/couples in a general
population. The aim of this study was to document the use of, and experiences related to, foetal scanning before
the recommended 19th week scan among pregnant women in Iceland.
Population and methods: The data come from the Icelandic Childbirth and Health Cohort Study 2009–11. A total
of 1111 women attending prenatal care at primary care health centres answered questionnaires before mid-
pregnancy and after birth, including questions about the number of scanning procedures during pregnancy. These
might include consumer-initiated ‘pregnancy confirmation scans,’ scans for clinical reasons, and screening for foetal
anomalies in week 11–14 which is optional in Iceland. The questionnaires also addressed parental decision-making
associated with the 11–14 week screening, perception of the pre-screening information, reasons for attending or
declining, and whether/how early foetal screening affected the women’s concerns related to the unborn child.
Results: A total of 95% of the women reported some kind of foetal ultrasound scanning before the 19th week
scan, and 64% reported two or more scans in this period. 78% of the women chose to participate in screening for
foetal anomalies in week 11–14. Decision-making in relation to this screening was mainly informed by sources
outside the healthcare system, and many women characterized participation as ‘self-evident’. Most women felt they
got sufficient information about the scope of screening, whilst information regarding potential downsides and risks
was frequently perceived as insufficient. Most women who chose the 11–14 week screening reported a reassuring
or neutral effect, whilst 10% of the women reported that it increased their concerns related to their unborn child.
Conclusions: Ultrasound scans in the first half of pregnancy are in high use in Iceland and have apparently
become part of a broader pregnancy culture, encompassing both high- and low-risk pregnancies. Whether this is a
favourable development or to some extent represents unwarranted medicalization, can be debated. More balanced
information might be provided prior to early screening for foetal anomalies.
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Background
Ultrasound scans play an increasing role in antenatal
care and culture in industrialized societies. The purpose
of such scanning can be complex. For many expecting
parents, confirmation of the pregnancy and a first ‘en-
counter’ with the child-to-be are a central motivation.
From the service provider’s point of view, the most im-
mediate aim is to confirm a viable pregnancy. Beyond
this, one focus is on pregnancy-related risk factors, in
particular determination of the term, number of em-
bryos and location of the placenta. Another focus might
be to examine the foetus for potential malformations,
diseases or syndromes, including Trisomy 21 (Down’s
syndrome) [1]. Systematic foetal screening typically in-
volves visual examination of the foetus by ultrasound
and measurement of foetal nuchal translucency (NT),
often combined with measuring certain biomarkers in
maternal blood in pregnancy week 11–14 (“combined
test”). A more recent method involves examination of
free foetal DNA in maternal blood, so-called Non Invasive
Prenatal Testing (NIPT) [2]. Due to the diversity and
complexity of prenatal testing, provision of information
prior to scanning/testing is a demanding issue [3, 4].
Why do women attend ultrasound scans in the
early phases of pregnancy?
Several studies have shown that visualization of a living,
thriving foetus might represent the most prominent mo-
tivation for attending an ultrasound scan, in addition to
confirming and dating the pregnancy [5–7]. Since the
scan as such has strong appeal to many people, it can be
hard to disentangle its biomedical purposes from the hu-
man wish to simply ‘see’ the foetus. Scanning technology
might thereby contribute substantially to shaping the
culture surrounding even low-risk pregnancies [8].
Foetal screening and informed participation
Many countries have introduced national screening pro-
grammes for foetal anomalies at an affordable price or
free of charge [9]. The well-established scan around
pregnancy week 19 is in several countries, including
Iceland, supplemented by an offer of early pregnancy
screening in week 11–14 (most often the combined test)
[10]. The test sensitivity for Down‘s syndrome is 90–95%
[11, 12]. In the presence of increased risk, the pregnant
woman is offered an invasive diagnostic procedure,
which carries approximately 1% risk for unintended
pregnancy loss. The cut-off point for offering invasive
testing is typically 1/250 or higher [11].
Prenatal screening involves complex technology and is
inherently value-laden [3–6, 13, 14]. As in all screening
programmes, potential participants are entitled to cor-
rect, understandable and balanced information, so as to
enable informed participation [15].
Current practice in Iceland
At the time of the present study, Iceland had 320,000 in-
habitants, with 70% living in the greater capital area.
Then and now, the Icelandic healthcare system resem-
bles the other Nordic Welfare states with some varia-
tions [16, 17]. Public primary healthcare is intended to
represent the entry point in most instances. There is,
however, no systematic referral or gatekeeping system
[18], and private specialists can be directly sought for a
relatively affordable fee.
Icelandic primary care, including maternity care, is car-
ried out at public healthcare centres staffed by GPs, mid-
wives, nurses and other auxiliary staff, sometimes including
consulting obstetricians (publicly employed). Maternal care
in accordance with Icelandic guidelines is free of charge. It
is to a large extent delivered by the primary care midwives,
starting no later than pregnancy week 12 [19]. In case of
risk pregnancies, primary care staff collaborate closely with
hospital obstetricians. The guidelines in Iceland have since
2008 recommended one ultrasound scan in week 19–20
(the 19th week scan). When pregnant women enter the pri-
mary healthcare system for their first visit, they should
however, according to the same guidelines, be asked if they
want information about early pregnancy screening for foetal
anomalies (the combined test, week 11–14). Such screening
is done at the National University Hospital in Reykjavik or
Akureyri hospital in North Iceland. Pre-test information is
available both in primary care and at the screening site [19].
As early foetal screening is not directly recommended in
the Icelandic guidelines, it is not free of charge, but costs
around 93 Euros [20].
As previously explained, Icelandic women who become
pregnant have, since before this study started, easy access
to private gynaecologists who employ ultrasound equip-
ment as part of their clinical routines. A high number of
women consequently have their pregnancies confirmed by
a scan, before signing up for public antenatal care [21].
The cost for such a consumer-initiated specialist consult-
ation with ultrasound scanning has a maximum fee of 117
Euro (in comparison, a primary care consultation with a
GP costs 10 Euro, the situation in the study period was
comparable). The content of the private consultations in
early pregnancy may evidently vary. It can be assumed
that a confirmatory scan is performed, and that informa-
tion about the optional 11–14 week screening programme
is provided. Beyond this, we have limited knowledge about
the expectant parents` ideas about, and experiences with,
ultrasound in the early phases of pregnancy, from a gen-
eral population perspective. We also lack knowledge about
the parents’ information level and decision-making related
to the foetal screening programme in week 11–14.
The aim of the present study was to explore the over-
all prevalence of prenatal ultrasound scanning before the
recommended foetal scan in week 19, including scans
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related to screening in week 11–14, among pregnant
women in Iceland. Furthermore, we explored where the
women sought/got information about prenatal screen-
ing, the parental decision-making process, perception of
the information received, and the impact of screening on
their concerns related to the foetus` health.
Methods
Our data come from the Icelandic Childbirth and Health
Study (C&H study) in 2009–2011. Its design and ques-
tionnaires were based on a similar cohort study on preg-
nant women carried out in Sweden 1999–2000, Kvinnors
upplevelse av barnafödande (the“KUB”study) [22–24]. It
is a population-based cross-sectional cohort study of preg-
nant women attending routine antenatal care at primary
healthcare centres. We used consecutive convenience
sampling methods, stratified according to residency. This
was to attain a distribution similar to the entire country,
with a ratio of 70:30 for urban versus rural residency. The
study is described in more detail elsewhere [23].
Participating women answered a comprehensive ques-
tionnaire around pregnancy week 16 (phase I). A total of
1111 participants replied, constituting 63% of the 1765
women who initially agreed to receive the questionnaire
(convenience sampling method). This constituted 23% of
all childbirths in 2009. Phase II was conducted 5–6
months postpartum (765 participants responded), and
phase III 18 to 24months after delivery (657 partici-
pants, i.e. 59% of the original 1111 sample). The present
analysis is based on phases I and II.
The survey questions included socio-demographic and ob-
stetric background and use of health care services, including:
ultrasound scans and screening for foetal anomalies, percep-
tion of received information, decision-making related to
prenatal tests, emotional well-being and pregnancy-related
concerns. Education was categorized as: comprehensive
school covering 10 years (primary), upper secondary schools
3–4 years after comprehensive school (secondary), and tech-
nical education/university less than 4 years and university
more than 4 years (higher education).
To test the general validity of the dataset, evaluation
was done for possible self-selection bias caused by drop-
out after phase I, as recommended by Fewtrell et al. [25].
This analysis showed that those who participated in both
phases I and II were at baseline older (p < .001) and with a
somewhat higher educational level (p = .001), compared to
those who participated only in phase I. No difference was
found regarding residency, civil status or parity.
Statistical analysis
We used Statistical Package for Social Sciences (SPSS)
for Windows, version 24.0. Descriptive data are pre-
sented as frequency and percentage. We used Pearson’s
Chi-Square test to assess significance between groups on
demographic variables. Binary logistic regression ana-
lyses were used to estimate the association between
groups, using crude odds ratio (OR) with 95% confi-
dence intervals (CI). We considered a two-tailed value of
p < .05 to be significant.
Ethics approval and consent to participate
The study was approved by the National Bioethical
Committee in Iceland (VSNb2008010023/03–1), and re-
ported to the Data Protection Authority (S3695/2008
LSL/). The study was also approved by the professional
authorities of the involved health care centres. Partici-
pant consent was not required for this analysis, as it is
based on a previously de-identified database for which
informed consent was obtained according to the Ice-
landic Bioethics Committee.
Results
Socio-demographic characteristics of the participants at
entry are shown in Table 1. Most participants were well-ed-
ucated, with 63% having higher education (more than 14
years in total). A total of 69% lived in the capital area, and
93% lived with a partner (data not shown in table).
A total of 95% (CI 93.1–95.8%) of the pregnant women
had undergone at least one ultrasound scan before the
recommended scan in week 19. Figure 1 shows the cu-
mulative percentage of the number of ultrasound scans
in pregnancy. As shown, 64% underwent two or more
scans, and 2% had four or more scans before the 19th
week scan.
Seventy-eight percent of the women had participated in
early screening for foetal anomalies in week 11–14 (Table 1).
Among women above 35 years, 88% chose the screening test,
as did 75% among 18–24 year-old-women. There were sub-
stantial differences in foetal screening participation rates be-
tween primipara and multipara women, women with high
versus low education level, and women in urban and rural
areas (Table 1).
To test potential recall bias regarding the number of
early scans, we compared the number of scans reported
by the same women in phases I and II. When the routine
scan in week 19 was excluded from the total reported in
phase II, the numbers corresponded well (Fig. 1).
After becoming pregnant, 55% of the women con-
sulted a private gynaecologist with ultrasound equip-
ment (Table 1). These women were subsequently more
likely to choose prenatal screening in week 11–14, com-
pared to women who attended primary care midwives or
GPs as their first contact (p < .001).
Table 2a shows how the decision to attend or decline
prenatal screening for foetal anomalies was reached. It ap-
pears that the decision was typically reached within the
family, marginally influenced by a healthcare professional.
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Half the women reported that they found it “self-evident”
to participate in this screening.
Table 3 shows how the participants evaluated the in-
formation they had received regarding the prenatal
screening, subsequent diagnostic tests and associated
risks. Most women were satisfied with the information
they got about the screening programme as such, but
less satisfied with the information about its potential
downsides and risks. Regarding experiences of the 11–
14 week screening, most women (92%) reported a posi-
tive experience (Table 2c).
As illustrated in Table 1, 22% of the included women
did not attend early screening for foetal malformations.
Table 2d shows the reasons women reported to underpin
this decision. As shown, the main reason was their per-
sonal values and views in general, followed by not con-
sidering their pregnancy/foetus to be at-risk, reluctance
to face a potential decision of whether or not to termin-
ate the pregnancy, and doubts regarding the reliability of
the test. Among women who underwent foetal screening
in week 11–14, the majority (61,5%) reported reduced
concerns regarding the unborn child’s health after the
test, 18% reported unchanged concerns, and 9,5% re-
ported increased concerns (Table 2b).
Discussion
The Icelandic Childbirth and Health Study is a compre-
hensive primary care cohort study on pregnancy and
childbirth. Although ultrasound before week 19 has so
far not become part of routine antenatal care in Iceland,
our data shows that 95% of all participating women had
at least one scan, and 64% had two or more scans in this
period. In many instances, the early scans seem to in-
volve one consumer-initiated “confirmation scan” with a
Table 1 Characteristics, obstetrical history and type of health care providers among participants at their first contact with the health
care service. Percentages (absolute figures within brackets), odds ratio (OR) and 95% confidence intervals (95%CI) for those who
chose combined prenatal screening test for foetal anomalies in the Childbirth and Health Study, Iceland
All (Number) % Combined prenatal screening test at week 11–14
% OR 95%CI p-value
Total 1111 78.3 (862/1101)
Parity at study entry
Primipara 439 39.5 (439/1110) 82.3 (359/436) 1 Ref.
Multipara 671 60.5 (671/1110) 75.6 (503/665) 0.67 0.49–0.90 .009
Education
Primary (10 years) 123 11.1 (123/1109) 73.0 (89/122) 0.53 0.34–0.83 .006
Secondary (4 years) 291 26.2 (291/1109) 67.9 (195/287) 0.42 0.30–0.58 .009
Higher (total > 14 years) 695 62.7 (695/1109) 83.5 (577/691) 1 Ref.
Age (years)
18–24 186 16.7 (186/1111) 75.0 (138/184) 0.39 0.23–0.69 .001
25–34 733 66.0 (733/1111) 76.5 (557/728) 0.43 0.27–0.69 <.001
> 35 192 17.3 (192/1111) 88.4 (168/190) 1 Ref.
Region
Urban 763 68.7 (763/1110) 86.5 (656/758) 1 Ref.
Rural 347 31.3 (347/1110) 60.1 (206/343) 0.23 0.17–0.32 <.001
I have tried to become pregnant for more than one year
Yes 147 13.3 (147/1106) 83.0 (122/147) 1 Ref.
No 959 86.7 (959/1106) 77.6 (737/950 0.71 0.45–1.12 .140
Assisted pregnancy such as in vitro fertilization or artificial insemination
Yes 67 6.1 (67/1106) 85.1 (57/67) 1 Ref.
No 1039 93.9 (1039/1106) 77.9 (802/1030) 0.62 0.31–1.23 .168
Type of health care provider as first contact in pregnancy
Midwife 320 29.1 (320/1110) 71.3 (228/320) 1 Ref.
General practitioner 129 11.7 (129/1110) 72.9 (94/129) 1.08 0.69–1.71 .730
Gynaecologist 609 55.4 (609/1110) 83.3 (507/609) 2.01 1.45–2.77 <.001
Others 42 3.8 (42/1110) 76.2 (32/429) 1.29 0.61–2.73 .504
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private gynaecologist, followed by the optional, early
screening for foetal anomalies in week 11–14, which was
chosen by 78% of the women. There were substantial
differences in screening participation between sub-
groups. This is likely to mirror varying accessibility to
secondary health care, as well as differing views of what
it means to be pregnant and how to behave in this situ-
ation. The fact that primipara women attended early
foetal screening more frequently than multipara women
(who are likely to be older with a higher statistical risk
of foetal anomalies) suggests that pregnant women’s mo-
tivations for ultrasound examinations in pregnancy are
not fixed, but can vary with time, life experience and
other circumstances. The complex impact foetal scan-
ning might have on pregnant women and their partners
has been discussed for decades, as can be illustrated by
Lumley’s 1990 paper “Through a glass darkly” [26]. Simi-
larly, the issue of medicalization of pregnancy has been
debated for years [27]. To what extent the frequent use
of ultrasound scanning found in this study represents a
favourable trend, or whether it entails a tendency
Fig. 1 Cumulative percentage of the number of ultrasound scans
before pregnancy week 19 (phase I, N = 1038). For validation,
recalled number of ultrasounds among respondents after delivery
(phase II; N = 763)
Table 2 Percentage (absolute figures within brackets) of the women’s main reasons for choosing or denying prenatal screening for
foetal anomalies in week 11–14 of pregnancy, potential concerns related to the unborn childs` health, their experience of the
screening test and the main reasons for declining the test
2a) Main reason for choosing to attend prenatal screening* % n/N 95% CI
My partner and I agreed on participating 74.5 636/854 0.71–0.77
To me it was self-evident to participate 49.6 424/854 0.46–0.53
Everyone I know have had the screening 4.8 41/854 0.04–0.06
Advice from doctor 4.9 42/854 0.04–0.07
The child’s father wanted me to participate 4.5 38/854 0.03–0.06
Advice from midwife 3.7 32/854 0.03–0.05
2b) Had the prenatal screening impact on your worries about whether something was wrong with the child?
Yes, it increased my concerns 9.5 79/828 0.08–0.12
Yes, it reduced my concerns 61.5 509/828 0.58–0.65
No, the screening did not affect my concerns 18.0 149/828 0.16–0.21
I never had any concerns there was something wrong with the child 11.0 91/828 0.09–0.13
2c) How would you describe your experience with the combined test?
Very positive 58.3 483/828 0.55–0.62
Positive 34.1 282/828 0.31–0.37
Neither positive nor negative 6.5 54/828 0.05–0.08
Negative 0.6 5/828 0.00–0.01
Very negative 0.5 4/828 0.00–0.01
2d) Why did you choose to not do the combined test? *
Do not consider myself at being at risk of having a child with foetal anomalies 39.0 92/234 0.33–0.46
Do not think I could make a decision if there was a possibility for foetal anomalies 38.9 91/234 0.33–0.45
Do not think it is reliable enough 26.1 61/234 0.21–0.32
My values and beliefs 52.6 123/234 0.46–0.59
*More than one option possible
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towards undue medicalisation of pregnancy and misuse
of healthcare resources, is open for debate.
A ‘self-evident’ test and an informed choice?
Our study indicates that the decision to attend prenatal
screening in week 11–14 was mainly made within the
family, and not directly initiated by a healthcare profes-
sional. The fact that many women found it “self-evident”
to participate, further suggests that among substantial
subgroups of women, early foetal screening has become
deeply embedded in the wider culture of pregnancy.
Interestingly, however, when asked about pre-screening
information about potential associated risks, many found
this unsatisfactory. Similar findings have been reported
from Sweden [5, 28]. This might stem from lacking, sub-
optimal or biased pre-screening information given by
the healthcare workers, but perhaps also from low re-
ceptivity to information on potential downsides of
screening among the women prior to the decision to
participate. Asking them later, as we did in our study,
might thereby elicit some afterthoughts. Seen together,
these findings lead us to question whether participation
in the 11–14 week screening represented an informed,
autonomous choice for the majority of the women. It
would be interesting to study the information process in
more detail at the different provider settings and levels.
As Williams [13] has pointed out, a general criticism of
prenatal screening is that the women might not realize
how much technology has come to influence the culture
surrounding pregnancy, nor what a genuinely free choice
actually entails. The main reason our responding women
gave for declining the early foetal screening test, was their
personal values and beliefs. Secondly, many said that they
did not consider themselves as “at-risk”. This is also in ac-
cordance with earlier studies on the subject [29, 30].
Comparison with other studies
To our knowledge, this is the first study of ultrasound
scanning among Icelandic women in the first half of preg-
nancy, until the recommended routine scan in week 19.
Data from the Icelandic Birth Registry [31] indicate
that 73% of pregnant women underwent early prenatal
Table 3 Perception of information given and odds (OR) for decision making regarding early prenatal NT* screening or the
combined test** for foetal anomalies at week 11–14. Percentages, absolute figures within brackets, odds ratios (OR) and 95%
confidence intervals (95% CI)
Number % Combined prenatal screening test at week 11–14
% OR 95% CI p-value
Information about availability of first trimester ultrasound scan
Enough or too much 906 84.2 (906/1076) 79.2 (718/906) 1 Ref.
Not enough 52 4.8 (52/1076) 75.0 (39/52) 0.79 0.41–1.50 .465
No information 118 11.0 (118/1076) 72.0 (85/118) 0.67 0.44–1.04 .075
Information about availability of early prenatal screening in week 11–14
Enough or too much 938 86.8 (938/1081) 79.6 (747/938) 1 Ref.
Not enough 69 6.4 (69/1081) 66.7 (46/69) 0.51 0.30–0.87 .012
None 74 6.8 (74/1081) 73.0 (54/74) 0.69 0.40–1.18 .176
Information about the potential risk of early prenatal screening in week 11–14
Enough or too much 521 48.3 (521/1078) 76.6 (399/521) 1 Ref.
Not enough 145 13.5 (145/1078) 80.7 (117/145) 1.28 0.81–2.02 .296
No information 412 38.2 (412/1078) 80.3 (331/412) 1.25 0.91–1.72 .168
Information about the potential risk associated with foetal prenatal diagnosis
Enough or too much 509 47.2 (509/1079) 78.0 (397/509) 1 Ref.
Not enough 153 14.2 (153/1079) 81.7 (125/153) 1.26 0.80–2.00 .326
No information 417 38.6 (417/1079) 78.2 (326/417) 1.01 0.74–1.38 .947
Information about upcoming/routine ultrasound scan in week 19–20
Enough or too much 815 75.5 (815/1080) 75.7 (617/815) 1 Ref.
Not enough 152 14.1 (152/1080) 85.5 (130/152) 1.90 1.17–3.06 .009
No information 113 10.5 (113/1080) 91.2 (103/113) 3.31 1.69–6.45 <.001
*NT Foetal nuchal translucency
**ß-hcg and PAPP-A measured in plasma and NT measurements by ultrasound
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screening in pregnancy week 11–14 in the year 2009
when this study started. This figure is slightly lower than
our finding of 78%, which can partly be explained by a
certain overrepresentation of highly educated women in
our material [32]. It might also be that some women in
our 2009 study misclassified an early clinical scan as for-
mal screening. Recent figures from the national Birth
Register in Iceland indicate that 80% of women currently
attend the combined screening test [31].
We have not found international data for comparison of
Icelandic women‘s use of early ultrasound in pregnancy. A
Swedish study showed that 36% of pregnant women in
year 2013 underwent combined screening [33]. This is
much lower than in our study. A Danish study from 2008
showed that the number of women who chose early foetal
screening increased from 63% in 2005 to 84% in 2006.
This can probably be explained by the introduction of an
offer of prenatal screening between 2004 to 2006 [34].
More recent numbers suggest that over 90% of Danish
women undergo the combined test [35].
Norway currently has no established programme for
early foetal screening. Experts in foetal medicine however
report that a high number of pregnant Norwegian women
seek out a private clinic and have an early ultrasound scan
done there, not unlike the Icelandic situation [36]. If that
scan is suggestive of anything abnormal, the woman is re-
ferred to an authorized department for foetal medicine.
This pathway can be described as an informal ‘back door’
to early foetal screening.
Strengths and weaknesses of the study
The main strength of our study is its size, encompassing
23% of all childbirths in Iceland in 2009. The original sam-
ple has been considered relatively representative [23, 32].
Our convenience sampling method is unlikely to have
resulted in serious selection bias, as the study addressed
women who attended routine antenatal care, with a
focus on their general experiences, thoughts and atti-
tudes as pregnant women in modern society. A certain
response bias could, however, not be avoided, as women
who ultimately answered the questionnaires are likely to
have been more interested in the research topics than
those who were initially positive, but did not return the
questionnaire [24].
Women with higher education might be somewhat over-
represented [32]. It is a weakness that the number of ultra-
sound scans are self-reported, but our test of potential
recall bias suggests that the overall numbers are quite reli-
able. Another weakness is the drop out between Phases I
(before mid-pregnancy) and II (after delivery). Several fac-
tors may have contributed to this. In 2009, the financial cri-
sis in Iceland led to substantial work-related emigration,
and it is likely that some of our original participants had left
the country. In addition, a few pregnancies are likely to
have ended unsuccessfully, diminishing the mother’s motiv-
ation to participate in Phase II. We do not have precise data
on these matters.
Conclusions
Ultrasound scans in early pregnancy are in high use in
Iceland and have apparently become a profiled part of
the pregnancy culture. We found substantial variations
regarding uptake of early foetal screening among sub-
groups. Whether the widespread use of early scanning
represents a favourable development or a sign of undue
medicalization and overuse of medical resources, can be
debated. Information prior to prenatal screening for
foetal anomalies might be improved, particularly regard-
ing potential side effects and risks associated with the
screening programme.
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